Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest ganciclovir Stories

2013-06-27 08:29:42

EXTON, Pa., June 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced updated data from the two ongoing, Phase 2 dose ranging studies investigating maribavir for both first line treatment of cytomegalovirus (CMV) viremia and treatment of resistant/refractory CMV. ViroPharma is currently conducting two Phase 2 dose ranging studies of oral maribavir at one of three doses (400mg, 800mg or 1200mg BID) in transplant recipients. The first is a randomized,...

2013-06-11 04:22:21

EXTON, Pa., June 11, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral (CMV) disease in patients with impaired cell mediated immunity. The "Orphan Medicinal Product Designation" is designed to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases identified as "life-threatening or chronically...

2013-06-10 23:16:57

Greenville, NC area Carolina Women´s Physicians practice advises its patients that June is National Congenital Cytomegalovirus Awareness Month. Greenville, NC (PRWEB) June 10, 2013 Carolina Women´s Physicians is advising their clientele that June is National Congenital Cytomegalovirus Awareness Month. Congenital Cytomegalovirus is the most common viral infection women pass along to infants (pregnancy or birth). The Centers for Disease Control & Prevention (CDC) estimates one...

2012-09-21 06:27:01

RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced data highlighting the significant morbidity and resource utilization associated with the current standard of care for the management of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. This analysis, entitled "Preemptive Therapy (PrT) for Cytomegalovirus (CMV) Post-hematopoietic Cell...

2012-07-09 06:28:09

RESEARCH TRIANGLE PARK, N.C., July 9, 2012 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced a late-breaking poster presentation at the 24th International Congress of the Transplantation Society being held July 15-19th, 2012 at the International Congress Centre Berlin in Berlin, Germany. The poster presentation, entitled "CMX001, a Novel Broad Spectrum Antiviral, May Mitigate Signs of BK Virus (BKV) Associated Bladder...

2012-07-05 10:24:02

PLEASANTON, Calif., July 5, 2012 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for a new test to assess a patient's viral load of cytomegalovirus (CMV). The fully automated COBAS® AmpliPrep / COBAS® TaqMan® CMV Test is the first FDA-approved laboratory test for use in quantifying CMV DNA in human plasma specimens. Physicians use CMV DNA viral load information from...

2012-06-04 02:25:36

EXTON, Pa., June 4, 2012 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent Phase 2 clinical studies that will include subjects at different ends of the spectrum of CMV infection or disease, namely those who have asymptomatic CMV, and those who have failed therapy with other anti-CMV agents....

2011-09-27 14:40:21

Researchers at Karolinska Institutet in Sweden have demonstrated for the first time that it is possible to inhibit the growth of brain tumors by treating the common Cytomegalovirus (CMV). The virus, which is found in a wide range of tumor types, offers a possible route towards controlling tumor growth and reducing the size of the tumor as a complement to conventional cytotoxin-based therapies. The CMV is a common virus that is found in 70-75 per cent of the adult population. Normally it is...

2010-09-28 08:42:00

MONMOUTH JUNCTION, N.J., Sept. 28 /PRNewswire/ -- Tamir Biotechnology, Inc. (Pink Sheets: ACEL) (formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also...

2010-09-15 12:22:00

Updated drug label will help prevent potential overdose in underweight transplant patients SILVER SPRING, Md., Sept. 15 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration is notifying health care professionals of updated dosing recommendations for Valcyte (valganciclovir) oral tablets and solution used by children and adolescents receiving a kidney or heart transplant. The update is intended to prevent drug overdosing of children with low body weight, low body surface area,...